Logo

Samsung Biologics Collaborates with Dinona to Develop DNP-019 for COVID-19

Share this

Samsung Biologics Collaborates with Dinona to Develop DNP-019 for COVID-19

Shots:

  • The companies collaborate for fast-track development of DNP-019 against COVID-19
  • The collaboration will expand Samsung’s CDO capabilities to provide a full scope of its development services from cell line development- process development- to non-clinical and clinical material manufacturing
  • Samsung has introduced its proprietary cell-line technology- S-CHOice- demonstrating improved titers up to two-fold and maintaining over 90% cell viability

 ­ Ref: PRNewswire | Image: Twitter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions